Biogen Inc. Stock
€175.30
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Biogen
sharewise wants to provide you with the best news and tools for Biogen, so we directly link to the best financial data sources.
Financials
News
Stoke Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Stoke Therapeutics, Inc.? Here are five stocks we like better.
- EMPEROR remains on schedule: Stoke completed enrollment ahead of plan with 162 Dravet syndrome patients
Biogen Q2 Earnings Call Highlights
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen’s second-quarter revenue rose 3% to $2.7 billion, driven by growth products and the newly acquired Apellis
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen says its Phase 2 CELIA study of tau-targeting Alzheimer’s drug diranersen missed the main dose-response
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
Key Points
- Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better.
- Ionis has a packed 2026-style catalyst calendar with two PDUFA dates for wholly owned drugs —
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen's diranersen missed its primary endpoint in the Phase 2 CELIA trial, sending BIIB shares down more than 10% on
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum
Key Points
- Interested in Arrowhead Pharmaceuticals, Inc.? Here are five stocks we like better.
- REDEMPLO is gaining momentum, with approvals in the U.S., China, Australia and Canada already in
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease
Why Biogen Stock Topped the Market Today
One of these enterprises was Biogen (NASDAQ: BIIB), which did quite well in its second quarter. As a reward, investors snapped up the stock, sending it to a nearly 2% gain on the day. This beat the
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
Biogen (NASDAQ: BIIB) built itself into a biotech giant thanks to its portfolio of multiple sclerosis (MS) drugs -- but in biotech and pharma, revenue growth depends on the life of a patent. Once a
Best Healthcare Stocks to Buy in 2026
Biogen (NASDAQ: BIIB) and Novo Nordisk (NYSE: NVO) represent different opportunities within the healthcare sector: One is a value-oriented play focusing on specialized neurology, while the other is
Why Biogen Stock Was a Winner on Wednesday
Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by
Why Biogen Stock Got Mashed on Monday
Healthcare company Biogen (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in
Why Biogen Stock Sank While the Market Soared on Thursday
Bullishness was in the air on the stock market on Tuesday, but you'd hardly know that from the performance of Biogen (NASDAQ: BIIB). The healthcare sector mainstay saw its share price slump by over